Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

77.25GBp
22 Jun 2018
Change (% chg)

-3.65 (-4.51%)
Prev Close
80.90
Open
80.75
Day's High
81.20
Day's Low
77.15
Volume
3,447,585
Avg. Vol
5,025,165
52-wk High
127.22
52-wk Low
68.00

Summary

Name Age Since Current Position

Bruno Angelici

71 2014 Non-Executive Chairman of the Board

James Ward-Lilley

51 2015 Chief Executive Officer, Executive Director

Frank Condella

2016 Non-Executive Vice Chairman of the Board

David Lescuyer

2016 Executive Vice President – Oral Business

Gonzalo Miquel

2017 Chief Medical Officer & Executive Vice President - Development

Geraldine Venthoye

2016 Executive Vice President - Pharmaceutical Development Appointment

John Murphy

62 2016 General Counsel ,Company Secretary

Joanne Hombal

42 2015 Director of Human Resources

Roger Heerman

43 2014 Chief Commercial Officer

Andrew Derodra

49 2018 Director

Per-Olof Andersson

64 2015 Non-Executive Director

Thomas Werner

62 2016 Non-Executive Director

Susan Foden

63 2016 Senior Independent Non-Executive Director

Neil Warner

63 2011 Non-Executive Independent Director

Anne Whitaker

50 2018 Independent Non-Executive Director

Fleur Wood

2012 IR Contact Officer

Biographies

Name Description

Bruno Angelici

Mr. Bruno F. J. Angelici, MBA, is Non-Executive Chairman of the Board of the Company, effective 1 February 2014. He was appointed to the Board of Vectura Group on 1 December 2013 and became Non-Executive Chairman on 1 February 2014. Bruno Angelici is a French national with an MBA (Kellogg School of Management) and business and law degrees from Reims. Bruno Angelici’s career includes senior management roles in pharmaceutical and medical device companies. Bruno Angelici retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa having originally joined as President of ICI Pharma France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. Bruno Angelici is a Non-Executive Director of Smiths Group plc, a FTSE 100 technology group, and Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is also a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd Japan, the largest pharmaceutical company in Asia, and a member of the Supervisory Board of Wolters Kluwer NV, a global information services and publishing company.

James Ward-Lilley

Mr. James Ward-Lilley is a Chief Executive Officer, Executive Director of the Company. James Ward-Lilley was appointed Chief Executive Officer of Vectura in September 2015. James is a BA Hons graduate, has an MBA and holds an Institute of Marketing Diploma. Prior to joining Vectura, James was vice president respiratory, inflammation & autoimmunity, Global Product and Portfolio Strategy (GPPS) at AstraZeneca. In this role James had responsibility for the development of AstraZeneca’s Respiratory, Inflammation and Autoimmunity (RIA) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics. Prior to this, James led the AstraZeneca investor relations team from 2011 to 2012. James had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to country head of Belgium and Luxembourg, a position he held between 2002 and 2005. He then led AstraZeneca’s business in China to become the number one pharmaceutical company in the market in 2008. James went on to become regional vice president for Central Eastern Europe and the Middle East, where the business enjoyed a period of strong growth, with sales doubling to US$2bn during his tenure.

Frank Condella

Mr. Frank Condella is Non-Executive Vice Chairman of the Board of the company. Frank Condella was appointed as non-executive chairman of Skyepharma on 1 January 2010, having originally joined that company’s board as chief executive officer in March 2006. Following the merger with Vectura, he was appointed to the Board on 10 June 2016 as Non-Executive Vice Chairman. He holds a BS in pharmacy and an MBA from Northeastern University, US. Frank brings over 30 years’ experience in the pharmaceutical industry to the Board. He is a non-executive director of Juniper Pharmaceuticals Inc. and Palladio Biosciences Inc. Previously, he was president and CEO of Juniper Pharmaceuticals, has served as a non-executive director of Fulcrum Pharma Ltd and Prosonix Ltd and was president of European Operations at IVAX, Chief executive officer of Faulding Pharmaceuticals, vice president of the Specialty Care Products business at Roche and vice president and general manager of the Lederle unit of American Home Products (Pfizer). Frank is a non-executive director of Juniper Pharmaceuticals Inc,. and Palladio Biosciences Inc,.

David Lescuyer

Mr. David Lescuyer is Executive Vice President – Oral Business of the company. David joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where he had been executive vice president – Oral business since April 2016. David, a French national, holds a BSc in mechanical engineering and an MBA from HEC Paris. David joined Skyepharma from Patheon Pharmaceuticals, where he was executive director and general manager, Patheon France, and more recently global VP, operational excellence. Prior to Patheon, David’s career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

Gonzalo Miquel

Mr. Gonzalo De Miquel is Chief Medical Officer & Executive Vice President - Development of the company. Gonzalo De Miquel joined Vectura in February 2017. Gonzalo has highly relevant medical and product development experience ranging from pharmacovigilance and regulatory through to early and late stage clinical development and medical affairs. Prior to joining Vectura, Gonzalo was Vice President of Clinical Development at Astra Zeneca with responsibility for the overall strategy, organisation, resource assignment and project prioritisation across Astra Zeneca’s portfolio. Gonzalo trained in Internal medicine and Rheumatology practising for six years in Barcelona before moving into the pharmaceutical industry. Gonzalo has held senior positions including global clinical lead for respiratory autoimmunity at Boehringer working in early clinical development as well as the late-stage and launch of Spiriva in Spain and with Almirall as Director of Global Clinical Development, successfully leading their aclidinium franchise development through to FDA and EMA approvals in 2012 and previously as their head of Global Medical Affairs.

Geraldine Venthoye

Ms. Geraldine Venthoye is Executive Vice President - Pharmaceutical Development Appointment of the company. Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president Pharmaceutical Development since 2013, having joined Skyepharma as Head of inhalation business unit in September 2003. Geraldine is a UK registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London. Geraldine held senior CMC leadership and scientific roles in Inhale/ Nektar Therapeutics, San Carlos, California, US, and prior to this in the UK, held scientific positions in inhalation drug delivery at Vandsons Research and Norton Healthcare.

John Murphy

Mr. John Murphy is General Counsel and Company Secretary of the company. John Murphy joined Skyepharma as General Counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger. John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

Joanne Hombal

Ms. Joanne Hombal serves as a Director of Human Resources of the Company. She joined Vectura in January 2015. Joanne has a BSc in psychology from the University of Birmingham, a postgraduate diploma in human resource management from the University of Glamorgan and is a Chartered Member of the Institute of Personnel and Development. Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has also held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

Roger Heerman

Mr. Roger Heerman is a Chief Commercial Officer and ,joined Vectura in 2010 and was appointed Senior Vice President, Commercial Strategy in 2013. Prior to joining Vectura, Roger gained extensive US and international commercialisation experience in a number of senior roles, including vice president sales and marketing of the US publicly held company Critical Therapeutics, Inc. and as vice president, director of client service at McK Healthcare. At Critical Therapeutics, he was responsible for the build-out of the commercial infrastructure and the launch of ZYFLO CR in the US. At McK Healthcare, Roger supported the launch and repositioning efforts of numerous US and global brands, including UCB’s Neupro® for Parkinson’s disease and IROKO’s Aggrastat® for acute coronary syndrome. Roger began his career in the pharmaceutical industry as a sales representative in the respiratory division at GlaxoSmithKline. He received his BS from Babson College and his MBA from the F.W. Olin School of Business at Babson College.

Andrew Derodra

Mr. Andrew Derodra is no longer Director of the Company., end of July 2018. He was Chief Financial Officer of the company. Andrew Derodra was appointed Chief Financial Officer (CFO) on 10 June 2016 having previously been appointed CFO of Skyepharma in November 2013. He is a Fellow of the Chartered Institute of Management Accountants and holds a BA (Hons) in mathematics from Oxford University.

Per-Olof Andersson

Dr. Per-Olof Andersson is a Non-Executive Director of the Company. Per-Olof joined the Vectura Board in April 2015. Per-Olof was born in Sweden and studied medicine at Lund University. Per-Olof has an international R&D track record within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industry and considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharmaceutical companies and, in particular, working with Almirall.

Thomas Werner

Mr. Thomas Werner is Non-Executive Director of the company. Thomas Werner was appointed to the Board of Skyepharma as a Non-Executive Director in May 2009 and joined the Board of Vectura following the merger in June 2016. He holds a degree in chemistry from the University of Göttingen. Thomas Werner has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline where he was managing director for Germany and also co-ordinated its European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. He has held various non-executive positions including Riemser Pharma GmbH and New Oncology AG. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies. Thomas is chairman of Fertin Pharma, a Danish medicated chewing gum company, and sits on the boards of Basilea Pharmaceutica Ltd and BSN Medical. He is chairman of the investor advisory committee of the Seventure (France) Health for Life capital investment fund.

Susan Foden

Dr. Susan Elizabeth Foden, Ph.D. is a Senior Independent Non-Executive Director of the Company. She joined the Board of Vectura as a Non-Executive Director in January 2007. She chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. She holds a number of Non-Executive Directorships with both public and private companies in the biotech and healthcare field, including Source Bioscience plc, Cizzle Biotechnology Ltd, BerGenBio AS and Evgen Ltd. Prior to this Susan Foden held positions in venture capital and UK biotech companies. From 2000 to 2003 she was an Investor Director with the London-based venture capital firm Merlin Biosciences Limited, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

Neil Warner

Mr. Neil William Warner is Non-Executive Independent Director of the Company. He joined the Board of Vectura as Non-Executive Director in February 2011. Neil Warner has significant financial and managerial experience in multi national businesses. Neil Warner is the Non-Executive Chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market. He was Finance Director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, he spent six years at Exel plc (formerly Ocean Group plc and acquired by Deutsche Post in December 2005) where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a Non-Executive Director of Dechra Pharmaceuticals plc where he was the Senior Independent Director and Chair of the Audit Committee. Neil Warner has an economics degree from the University of Leeds and is a Fellow of the Institute of Chartered Accountants.

Anne Whitaker

Ms. Anne Whitaker has been appointed as Independent Non-Executive Director of the Company., with effect from 1 June 2018. Anne has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and speciality pharma companies. She has significant experience in the US respiratory sector and was, until recently, serving as President and Chief Executive Officer of KNOW Bio, LLC and its wholly owned subsidiary, Novoclem Therapeutics, Inc., a company focused on helping patients who suffer from severe respiratory diseases. Previously, Anne was Executive Vice President and Company Group Chairman at Valeant Pharmaceuticals, where she was responsible for overseeing its Branded Pharmaceutical Business. Prior to that, Anne served as President and Chief Executive Officer of Synta Pharmaceuticals, now part of Madrigal Pharmaceuticals, Inc. She also served as President, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations for the region, and held several commercial leadership roles at GlaxoSmithKline. Anne is currently an Independent Director of Cree, Inc., a NASDAQ traded company and has been nominated to serve as an independent director of Mallinckrodt plc pending their shareholder vote at the Annual General Meeting in May, 2018.

Fleur Wood